Provectus Biopharmaceuticals, Inc. (PVCT) stock
PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05+0.00 (+0.39%)
Close on Oct 19, 2026Market cap $20.55MP/E –Yield –
Provectus Biopharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Provectus Biopharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$4.58M. For fiscal 2025 it was -$5.29M. The highest annual figure on record is -$2.90M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.29M | – |
| FY2024 | Dec 31, 2024 | -$4.53M | – |
| FY2023 | Dec 31, 2023 | -$2.90M | – |
| FY2022 | Dec 31, 2022 | -$3.43M | – |
| FY2021 | Dec 31, 2021 | -$4.67M | – |
| FY2020 | Dec 31, 2020 | -$4.96M | – |
| FY2019 | Dec 31, 2019 | -$6.30M | – |
| FY2018 | Dec 31, 2018 | -$8.05M | – |
| FY2017 | Dec 31, 2017 | -$13.32M | – |
| FY2016 | Dec 31, 2016 | -$24.51M | – |
| FY2015 | Dec 31, 2015 | -$24.65M | – |
| FY2014 | Dec 31, 2014 | -$12.63M | – |
| FY2013 | Dec 31, 2013 | -$13.03M | – |
| FY2012 | Dec 31, 2012 | -$14.34M | – |
| FY2011 | Dec 31, 2011 | -$21.44M | – |
| FY2010 | Dec 31, 2010 | -$20.69M | – |
| FY2009 | Dec 31, 2009 | -$12.33M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$938.68K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.25M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.12M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.28M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.10M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.33M | – |
| Q3 FY2024 | Sep 30, 2024 | -$955.73K | – |
| Q2 FY2024 | Jun 30, 2024 | -$794.85K | – |
| Q1 FY2024 | Mar 31, 2024 | -$447.27K | – |
| Q4 FY2023 | Dec 31, 2023 | -$604.69K | – |
| Q3 FY2023 | Sep 30, 2023 | -$714.15K | – |
| Q2 FY2023 | Jun 30, 2023 | -$800.20K | – |
| Q1 FY2023 | Mar 31, 2023 | -$782.21K | – |
| Q4 FY2022 | Dec 31, 2022 | -$683.72K | – |
| Q3 FY2022 | Sep 30, 2022 | -$666.19K | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.05M | – |
| Q2 FY2021 | Jun 30, 2021 | -$1.22M | – |
| Q1 FY2021 | Mar 31, 2021 | -$1.18M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.20M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.21M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.45M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.22M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.80M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.90M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.70M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.73M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.99M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.30M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.18M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.78M | – |
See a number that looks wrong?